SCHEMBL510345

SCHEMBL510345

O=Cc1cccc(-c2ccccn2)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TLR4 O00206 1/20 0.61
TLR2 O60603 1/20 0.61
CYP2A6 P11509 1/20 0.50
CDK8 P49336 1/20 0.47
AXL P30530 1/20 0.46
KDM4E B2RXH2 2/20 0.45
LMNA P02545 2/20 0.45
CCR1 P32246 2/20 0.45
CCR5 P51681 2/20 0.45
CCR8 P51685 2/20 0.45
CYP1A2 P05177 1/20 0.45
POLB P06746 1/20 0.45
METAP1 P53582 1/20 0.45
BLM P54132 1/20 0.45
HIF1A Q16665 1/20 0.45
DOHH Q9BU89 1/20 0.45
P4HTM Q9NXG6 1/20 0.45
ERN1 O75460 1/20 0.44
HTR1A P08908 1/20 0.44
HTR7 P34969 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29442907 1.00 TLR4 (0.61) TLR4TLR2CYP2A6CDK8AXL
SCHEMBL9665633 0.89 TLR4 (0.49) TLR4TLR2CYP2A6CDK8AXL
Dipyridyl SCHEMBL28723689 0.87 KDM4E (0.59) TLR4TLR2CYP2A6KDM4ELMNA
SCHEMBL6660140 0.83 TLR4 (0.63) TLR4TLR2CYP2A6KDM4ELMNA
SCHEMBL6660136 0.83 TLR4 (0.63) TLR4TLR2CYP2A6KDM4ELMNA
SCHEMBL5464094 0.82 TLR4 (0.57) TLR4TLR2CYP2A6KDM4ELMNA
SCHEMBL7120047 0.82 TLR4 (0.57) TLR4TLR2CYP2A6KDM4ELMNA
SCHEMBL30903581 0.82 TLR4 (0.57) TLR4TLR2CYP2A6KDM4ELMNA
SCHEMBL28903052 0.81 ABL1 (0.46) TLR4TLR2CYP2A6KDM4ELMNA
SCHEMBL31558286 0.81 TLR4 (0.64) TLR4TLR2CYP2A6KDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 226 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115960090-B Preparation method of rhodamine B modified pyridine ligand and photocatalytic antibacterial application thereof 中山大学 2024-03-29 CN claimed
CN-115960090-A Preparation method of rhodamine B modified pyridine ligand and photocatalytic antibacterial application thereof 中山大学 2023-04-14 CN claimed
CN-110407883-B Preparation method and application of iridium complex with 3- (2-pyridyl) -benzaldehyde as main ligand 陕西师范大学 2022-02-18 CN claimed
CN-100343256-C Biaryl substituted diazabicycloalkane amides as nicotinic acetylcholine agonists ASTRAZENECA AB (SE) 2007-10-17 CN claimed
CN-1678615-A Biaryl substituted diazabicycloalkanes as nicotinic acetylcholine antagonists ASTRAZENECA AB (SE) 2005-10-05 CN claimed
US-12570675-B2 Boronic acid compounds LG CHEM, LTD. (KR) 2026-03-10 US disclosed
CN-115960090-B Preparation method of rhodamine B modified pyridine ligand and photocatalytic antibacterial application thereof 中山大学 2024-03-29 CN disclosed
US-20240101579-A1 BORONIC ACID COMPOUNDS LG CHEM, LTD. (KR) 2024-03-28 US disclosed
CN-115093410-B Preparation method of beta-carboline compound 南京工业大学 2023-09-26 CN disclosed
EP-4242213-A1 BORONIC ACID COMPOUND Lg Chem, Ltd. (KR) 2023-09-13 EP disclosed
CN-116568310-A Boric acid compounds 株式会社LG化学 2023-08-08 CN disclosed
CN-115960090-A Preparation method of rhodamine B modified pyridine ligand and photocatalytic antibacterial application thereof 中山大学 2023-04-14 CN disclosed
US-6410736-B1 CENTRAL NERVOUS SYSTEM DISORDERS PFIZER INC. 2002-06-25 US disclosed
WO-2002046204-A1 6-0-CARBAMOYL KETOLIDE DERIVATIVES OF ERYTHROMYCIN USEFUL AS ANTIBACTERIALS ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2002-06-13 WO disclosed
WO-2002042275-A1 2-ARYL-5-TRIFLUOROMETHYLPYRIDINES BASF AKTIENGESELLSCHAFT (DE) 2002-05-30 WO disclosed
CN-1321153-A telomerase inhibitors and methods of use thereof GERON CORP (US) 2001-11-07 CN disclosed
EP-1115693-A1 SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL $i(TERTIARY)-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY Monsanto Company (US) 2001-07-18 EP disclosed
WO-2001027068-A1 BIARYL ETHER DERIVATIVES USEFUL AS MONOAMINE REUPTAKE INHIBITORS PFIZER PRODUCTS INC. (US) 2001-04-19 WO disclosed
CN-1252070-A 5,7-disubstituted 4-aminopyrido [2,3,-d] pyrimidine compounds and their use as adenosine kinase inhibitors ABBOTT LAB (US) 2000-05-03 CN disclosed
WO-2000018721-A1 SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL TERTIARY-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY MONSANTO COMPANY (US) 2000-04-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12570675-B2 Boronic acid compounds PSMB6, PSMB3, PSMB2 TLR4 2938/4885TLR2 1648/4885CYP2A6 125/4885
US-20240101579-A1 BORONIC ACID COMPOUNDS PSMB11, PSMB1, BACH1 TLR4 2289/4885TLR2 1904/4885CYP2A6 805/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.